Delisting risk
XTLB · NASDAQ · Biotechnology

XTL Biopharmaceuticals (ADR) (XTLB)

Develops psychedelic therapies and active ingredients through Psyga Bio.

$2.58
Pre-market−0.08 (−3.01%)
At close$2.66(+14.66%)

Breakdown13F · 13D/G · Form 4

Institutions6 holders · as of Mar 31, 20260.77%72.7K ADS
Otherremainder99.23%9.39M ADS

9.46M ADS (1 ADS = 100 ordinary shares) as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing

The share count is from the company's Dec 2022 annual report; nothing newer is on file here.

A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.

Top shareholders13F · 13D/G · Form 4

HolderStakeSharesEvidence
Noked Israel LtdInstitution
0.53%49,722 ADS13Fas of Mar 31, 2026
Smartharvest Portfolios, LLCInstitution
0.14%13,351 ADS13Fas of Mar 31, 2026
Rhumbline AdvisersInstitution
0.06%5,987 ADS13Fas of Mar 31, 2026
Gamma Investing LLCInstitution
0.04%3,388 ADS13Fas of Mar 31, 2026
Tower Research Capital LLC (TRC)Institution
0.00%244 ADS13Fas of Mar 31, 2026
Morgan StanleyInstitution
0.00%10 ADS13Fas of Mar 31, 2026
Daniel B. AsherInsider
0.70% of class, as filed13Gfiled Feb 27, 2017

13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more

Institutions13F, as of Mar 31, 2026

6 holders · 72.7K shares

HolderShares% outstandingChg q/qFiled
Noked Israel Ltd49.7K0.53%May 14, 2026
Smartharvest Portfolios, LLC13.4K0.14%Apr 21, 2026
Rhumbline Advisers6.0K0.06%May 12, 2026
Gamma Investing LLC3.4K0.04%Apr 6, 2026
Tower Research Capital LLC (TRC)2440.00%May 15, 2026
Morgan Stanley100.00%May 15, 2026

Ownership statements13D/G · 5% or more, as filed

No 13D/G filer at 5% or more on record.

Insider tradesForm 4

Latest trades

Nothing filed in the last 12 months.

CongressHouse and Senate disclosures

Not reported.